Statins and the elderly: Recent evidence and current indications

Aging Clinical and Experimental Research

Volumn 24, Issue SUPPL.3, 2012, Pages 47-55

  Schiattarella, Gabriele Giacomo ^a   Perrino, Cinzia ^a   Magliulo, Fabio ^a   Ilardi, Federica ^a   Serino, Federica ^a   Trimarco, Valentina ^a   Izzo, Raffaele ^a   Amato, Bruno ^a   Terranova, Claudio ^b   Cardin, Fabrizio ^b   Militello, Carmelo ^b   Leosco, Dario ^a   Trimarco, Bruno ^a   Esposito, Giovanni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Cardiovascular disease; Elderly; Prevention; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DISEASE ASSOCIATION; ELDERLY CARE; GENOTYPE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIVER DISEASE; MUSCLE WEAKNESS; PRIMARY PREVENTION; PROSPECTIVE STUDY; RISK REDUCTION; SECONDARY PREVENTION; SENILE DEMENTIA; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION;

EID: 84872711981     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.
2. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006; 77: 826-9.
3. Barton M. Aging and biomedicine 2005: where should we go from here? Cardiovasc Res 2005; 66: 187-9.
4. Hazzard WR, Ettinger WH Jr. Aging and atherosclerosis: changing considerations in cardiovascular disease prevention as the barrier to immortality is approached in old age. Am J Geriatr Cardiol 1995; 4: 16-36.
5. Amato B, Iuliano GP, Markabauoi AK et al. Endovascular procedures in critical leg ischemia of elderly patients. Acta biomedica: Atenei Parmensis 2005; 76 (Suppl 1): 11-5.
6. Galasso G, Piscione F, Furbatto F et al. Abciximab in elderly with acute coronary syndrome invasively treated: effect on outcome. Int J Cardiol 2008; 130: 380-5.
7. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996; 27: 373-80.
8. Marini C, Baldassarre M, Russo T et al. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology 2004; 62: 77-81.
9. Catapano AL, Reiner Z, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidemias. The Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3-46.
10. Wenger NK. Enrollment and maintenance of elderly patients in cardiovascular clinical trials. Am J Geriatr Cardiol 2006; 15: 352-6.
11. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003; 55: 604-8.
12. Strandberg TE, Pitkala K, Kulp S, Tilvis RS. Use of cardiovascular drugs by homedwelling coronary patients aged 75 years and older. A population-based cross-sectional survey in Helsinki, Finland. Eur J Clin Pharmacol 2001; 57: 513-6.
13. Lawlor DA, Whincup P, Emberson JR, Rees K, Walker M, Ebrahim S. The challenge of secondary prevention for coronary heart disease in older patients: findings from the British Women's Heart and Health Study and the British Regional Heart Study. Fam Pract 2004; 21: 582-6.
14. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006; 113: e409-49.
15. Amarenco P, Bogousslavsky J, Callahan A 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.
16. Alessandri C, Peverini F. [Hypercholesterolemia: therapeutic approach]. La Clinica terapeutica 1991; 137: 373-97.
17. Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev 2010; 18: 298-304.
18. Indolfi C, Cioppa A, Stabile E et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 2000; 35: 214-21.
19. Indolfi C, Di Lorenzo E, Perrino C et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002; 106: 2118-24.
20. Franzone A, Schiattarella GG, Capretti G et al. Biological effects of statins in atherosclerosis [Gli effetti biologici delle statine nella malattia aterosclerotica]. Trends in Medicine 2009; 9(1).
21. Perrino C, Feliciello A, Schiattarella GG et al. AKAP121 down-regulation impairs protective cAMP signals, promotes mitochondrial dysfunction, and increases oxidative stress. Cardiovasc Res. 2010; 88: 101-10.
22. Esposito G, Perrino C, Cannavo A et al. EGFR transactivation by urotensin II receptor is mediated by beta-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy. Basic Res Cardiol 2011; 106: 577-89.
23. Indolfi C, Torella D, Cavuto L et al. Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation 2001; 103: 2980-6.
24. Indolfi C, Esposito G, Stabile E et al. A new rat model of small vessel stenting. Basic Res Cardiol 2000; 95: 179-85.
25. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116: 408-16.
26. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-32.
27. Brugts JJ, Yetgin T, Hoeks SE et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
28. Ilardi F, Magliulo F, Gargiulo G et al. Endovascular treatment of carotid artery stenosis: evidences from randomized controlled trials and actual indications. Monaldi Archives for Chest Disease [Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro, IRCCS] and [Istituto di clinica tisiologica e malattie apparato respiratorio], Università di Napoli II, 2011; 76: 183-91.
29. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52: 1769-81.
30. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008; 51: 37-45.
31. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk of mortality in the oldest old. Lancet 1997; 350: 1119-23.
32. Shipley MJ, Pocock SJ, Marmot MG. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow-up in Whitehall Study. BMJ 1991; 303: 89-92.
33. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet 2001; 358: 351-5.
34. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291: 1864-70.
35. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective Studies Collaboration. Lancet 1995; 346: 1647-53.
36. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-31.
37. Williams MA, Fleg JL, Ades PA et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > or = 75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002; 105: 1735-43.
38. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
39. Hlatky MA. Expanding the orbit of primary prevention - moving beyond JUPITER. N Engl J Med 2008; 359: 2280-2.
40. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
41. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 1995; 76: 474-9.
42. Miettinen TA, Pyorala K, Olsson AG et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96: 4211-8.
43. Pan HY, Waclawski AP, Funke PT, Whigan D. Pharmacokinetics of pravastatin in elderly vs young men and women. Ann Pharmacother 1993; 27: 1029-33.
44. Lewis SJ, Moye LA, Sacks FM et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129: 681-9.
45. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3: 186-91.
46. Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 2004; 62: 1984-9.
47. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2. pii: a006239. doi: 10.1101/cshperspect.a006239.
48. Genin E, Hannequin D, Wallon D et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011; 16: 903-7.
49. Thompson GR. Cardiovascular disease prevention and the rise in dementia. QJM 2012; 105: 93-7.
50. Gerdes LU, Gerdes C, Kervinen K et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian Simvastatin Survival Study. Circulation 2000; 101: 1366-71.
51. Pac-Soo C, Lloyd DG, Vizcaychipi MP, Ma D. Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration. J Alzheimers Dis 2011; 27: 1-10.
52. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology. 2004; 23: 94-8.
53. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009; 80: 13-7.
54. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2009:CD003160.
55. Trompet S, van Vliet P, de Craen AJ et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010; 257: 85-90.
56. ten Dam VH, Box FM, de Craen AJ et al. Lack of effect of pravastatin on cerebral blood flow or parenchymal volume loss in elderly at risk for vascular disease. Stroke 2005; 36: 1633-6.
57. Sano M, Bell KL, Galasko D et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 77: 556-63.
58. Feldman HH, Doody RS, Kivipelto M et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010; 74: 956-64.
59. Gazzerro P, Proto MC, Gangemi G et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 2012; 64: 102-46.
60. Chiu HF, Ho SC, Chang CC, Wu TN, Yang CY. Statins are associated with a reduced risk of gastric cancer: a population-based case-control study. Am J Gastroenterol 2011; 106: 2098-103.
61. Cheng MH, Chiu HF, Ho SC, Yang CY. Statin use and the risk of female lung cancer: a population-based case-control study. Lung Cancer 2012; 75: 275-9.
62. Chiu HF, Kuo CC, Kuo HW, Lee IM, Lee CT, Yang CY. Statin use and the risk of kidney cancer: a population-based case-control study. Exp Opin Drug Safety 2012; 11: 543-9.
63. Perrino C, Schiattarella GG, Magliulo F et al. Cardiac side-effects of chemotherapy: state of the art and strategies for a correct management. Curr Vasc Pharmacol 2012 May 8. [Epub ahead of print]
64. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007; 50: 409-18.
65. Mausner-Fainberg K, Luboshits G, Mor A et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008; 197: 829-39.
66. Mallat Z, Ait-Oufella H, Tedgui A. Regulatory T cell responses: potential role in the control of atherosclerosis. Curr Opin Lipidol 2005; 16: 518-24.
67. Yakirevich E, Resnick MB. Regulatory T lymphocytes: pivotal components of the host antitumor response. J Clin Oncol 2007; 25: 2506-8.
68. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-74.
69. Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-80.
70. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
71. Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol 2007; 211: 144-56.
72. Hunt D, Young P, Simes J et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001; 134: 931-40.
73. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK. Outcomes of using high or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147: 1-9.
74. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
75. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested casecontrol studies. BMC Cancer 2011; 11: 409.
76. Berard E, Bongard V, Dallongeville J, Arveiler D, Ruidavets JB, Ferrieres J. Cancer mortality according to lipid-lowering drugs and lipoproteins in a general population. Curr Med Res Opin 2011; 27: 1963-71.
77. Cacciatore F, Abete P, Maggi S et al. Disability and 6-year mortality in elderly population. Role of visual impairment. Aging Clin Exp Res 2004; 16: 382-8.
78. Cornoni-Huntley JC, Foley DJ, Guralnik JM. Co-morbidity analysis: a strategy for understanding mortality, disability and use of health care facilities of older people. Int J Epidemiol 1991; 20 (Suppl 1): S8-17.
79. Lacas A, Rockwood K. Frailty in primary care: a review of its conceptualization and implications for practice. BMC Med 2012; 10: 4.
80. Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 2011; 9: 364-77.
81. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 2003; 17: 265-85.
82. Roberts WC. The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease. Am J Cardiol 1996; 78: 377-8.
83. Boscolo-Berto R, Viel G, Cecchi R et al. Journals publishing bio-medicolegal research in Europe. Int J Legal Med 2012; 126: 129-37.
84. Berthold HK, Gouni-Berthold I. Lipid-lowering drug therapy in elderly patients. Curr Pharm Des 2011; 17: 877-93.
85. Acharjee S, Welty FK. Atorvastatin and cardiovascular risk in the elderly - patient considerations. Clin Interv Aging 2008; 3: 299-314.